RecruitingNCT06920459

Zimmer Biomet Shoulder Arthroplasty PMCF Study

Zimmer Biomet Shoulder Arthroplasty Long-term Post Market Clinical Follow-up Study


Sponsor

Zimmer Biomet

Enrollment

40 participants

Start Date

Apr 29, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This is a multicenter, prospective, non-controlled post market surveillance study. The objectives of this study are to confirm the safety, performance, and clinical benefits of the Zimmer Biomet Shoulder Arthroplasty systems in primary anatomic shoulder arthroplasty and its instrumentation. Safety of the systems will be assessed by monitoring the frequency and incidence of adverse events. The performance and clinical benefits will be evaluated by assessment of the overall pain and functional performance, qualify of life, and radiographic parameters of all enrolled study subjects.


Eligibility

Min Age: 20 Years

Inclusion Criteria8

  • Patient must be 20 years of age or older.
  • Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants.
  • Patient is a candidate for shoulder arthroplasty due to one or more of the following:
  • Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
  • Rheumatoid arthritis. Fractures of the proximal humerus, where other methods of treatment are deemed inadequate.
  • Difficult clinical management problems, where other method of treatment may not be suitable or may be inadequate.
  • Patient must be able and willing to complete the protocol required follow-up.
  • Patient must be able and willing to sign the IRB/EC approved informed consent.

Exclusion Criteria11

  • Patient is unwilling or unable to give consent or to comply with the follow-up program.
  • Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study.
  • Patient is known to be pregnant or breastfeeding.
  • Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and/or anticipated to be non- compliant).
  • Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions.
  • Patient has any sign of infection affecting the shoulder joint or in its proximity which may spread to the implant site.
  • Patient has rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram.
  • Patient has any neuromuscular disease compromising the affected limb that would render the procedure unjustifiable.
  • Patient presents with osteoporosis, which in the opinion of the Investigator, may limit the subject's ability to support total shoulder arthroplasty using the study device.
  • Patient has a metabolic disorder that may impair bone formation.
  • Patient has osteomalacia.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEAlliance™ Glenoid

Total Shoulder Arthroplasty using the Alliance™ Glenoid implant


Locations(2)

ARCUS Kliniken Pforzheim

Pforzheim, Germany

Meander Medisch Centrum

Amersfoort, TZ, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06920459


Related Trials